Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director · 10% owner | June 18, 2021 | June 22, 2021 |
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 09, 2022 | June 10, 2022 |
| Monte Rosa Therapeutics, Inc.GLUE · Entity 4828 | Director · 10% owner | June 28, 2021 | June 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date June 18, 2021 · Filed June 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.55 · Expires 2031-06-17 | Direct | 15,000 |
Reported balance
After 2021-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-18 · Grant · Acquired 15,000 · Balance 15,000 F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders.
CRISPR Therapeutics AG
Report date June 09, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.70 · Expires 2032-06-09 | Direct | 12,000 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 12,000 · Balance 12,000 F1: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders.
Monte Rosa Therapeutics, Inc.
Report date June 28, 2021 · Filed June 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital VI, L.P. | 6,799,115 |
Reported balance
After 2021-06-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-06-28 · Conversion · Acquired 6,515,869 · Balance 6,799,115 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Vantage I, L.P. | 2,097,938 |
Last balance in matching sequence
After 2021-06-28 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2021-06-28 · Conversion · Acquired 1,940,043 · Balance 1,940,043 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Row 3 · 2021-06-28 · Purchase · Acquired 157,895 · Balance 2,097,938 F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series A convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Capital VI, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-06-28 · Conversion · Disposed 20,004,280 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Capital VI, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-06-28 · Conversion · Disposed 3,000,000 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Vantage I, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-06-28 · Conversion · Disposed 4,150,000 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series C convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Vantage I, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-06-28 · Conversion · Disposed 2,699,328 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries B Preferred Stock · Derivative | 452,630 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · derivative · entry 19 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 150,085 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F5 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F5 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F5 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F3 · ownership.nature: Shares held by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). The Reporting Person may be deemed to beneficially own indirectly 635,309 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, the general partner of Versant Ventures VI GP, the general partner of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP"), the general partner of Versant I Parallel. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries B Preferred Stock · Derivative | 1,970,572 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · derivative · entry 18 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 653,412 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F5 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F5 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F5 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F1 · ownership.nature: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). The Reporting Person may be deemed to beneficially own indirectly 6,413,332 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP"), the general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP"), the general partner of Versant VI. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), or for any other purpose. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries A Preferred Stock · Derivative | 3,851,526 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · derivative · entry 17 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,277,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F2 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F2 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F2 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F4 · ownership.nature: Shares held by Versant Voyageurs I, L.P.("Versant Voyageurs I"). The Reporting Person may be deemed to beneficially own indirectly 2,130,579 shares of Common Stock by reason of the Reporting Person has a beneficial interest in Versant Voyageurs I GP Company, the general partner of Versant Voyageurs I. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries A Preferred Stock · Derivative | 1,148,474 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · derivative · entry 16 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 380,817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F2 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F2 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F2 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F3 · ownership.nature: Shares held by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). The Reporting Person may be deemed to beneficially own indirectly 635,309 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, the general partner of Versant Ventures VI GP, the general partner of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP"), the general partner of Versant I Parallel. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries A Preferred Stock · Derivative | 15,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · derivative · entry 15 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 4,973,787 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F2 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F2 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F2 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F1 · ownership.nature: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). The Reporting Person may be deemed to beneficially own indirectly 6,413,332 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP"), the general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP"), the general partner of Versant VI. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), or for any other purpose. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 396,081 | $19.00 | $7,525,539.00 |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · nonDerivative · entry 14 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,206,603 F11 · shares: On February 3, 2020, Versant Vantage I purchased 396,081 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. F7 · ownership.nature: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). The Reporting Person may be deemed to beneficially own indirectly 810,522 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Vantage I GP-GP, LLC, the general partner of Versant Vantage I GP, L.P., the general partner of Versant Vantage I, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 396,082 | $19.00 | $7,525,558.00 |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · nonDerivative · entry 13 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,809,414 F10 · shares: On February 3, 2020, Versant VI purchased 396,082 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. F1 · ownership.nature: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). The Reporting Person may be deemed to beneficially own indirectly 6,413,332 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP"), the general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP"), the general partner of Versant VI. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), or for any other purpose. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 23,560 | $19.00 | $447,640.00 |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · nonDerivative · entry 12 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 658,869 F9 · shares: On February 3, 2020, Versant I Parallel purchased 23,560 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. F3 · ownership.nature: Shares held by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). The Reporting Person may be deemed to beneficially own indirectly 635,309 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, the general partner of Versant Ventures VI GP, the general partner of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP"), the general partner of Versant I Parallel. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 79,013 | $19.00 | $1,501,247.00 |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · nonDerivative · entry 11 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,209,592 F8 · shares: On February 3, 2020, Versant Voyageurs I purchased 79,013 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. F4 · ownership.nature: Shares held by Versant Voyageurs I, L.P.("Versant Voyageurs I"). The Reporting Person may be deemed to beneficially own indirectly 2,130,579 shares of Common Stock by reason of the Reporting Person has a beneficial interest in Versant Voyageurs I GP Company, the general partner of Versant Voyageurs I. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 350,141 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · nonDerivative · entry 10 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,130,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F4 · ownership.nature: Shares held by Versant Voyageurs I, L.P.("Versant Voyageurs I"). The Reporting Person may be deemed to beneficially own indirectly 2,130,579 shares of Common Stock by reason of the Reporting Person has a beneficial interest in Versant Voyageurs I GP Company, the general partner of Versant Voyageurs I. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 104,407 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · nonDerivative · entry 9 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 635,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F3 · ownership.nature: Shares held by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). The Reporting Person may be deemed to beneficially own indirectly 635,309 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, the general partner of Versant Ventures VI GP, the general partner of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP"), the general partner of Versant I Parallel. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 454,548 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · nonDerivative · entry 8 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,413,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F1 · ownership.nature: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). The Reporting Person may be deemed to beneficially own indirectly 6,413,332 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP"), the general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP"), the general partner of Versant VI. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), or for any other purpose. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 810,522 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 810,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F7 · ownership.nature: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). The Reporting Person may be deemed to beneficially own indirectly 810,522 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Vantage I GP-GP, LLC, the general partner of Versant Vantage I GP, L.P., the general partner of Versant Vantage I, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 503,327 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,780,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F4 · ownership.nature: Shares held by Versant Voyageurs I, L.P.("Versant Voyageurs I"). The Reporting Person may be deemed to beneficially own indirectly 2,130,579 shares of Common Stock by reason of the Reporting Person has a beneficial interest in Versant Voyageurs I GP Company, the general partner of Versant Voyageurs I. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 150,085 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 530,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F3 · ownership.nature: Shares held by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). The Reporting Person may be deemed to beneficially own indirectly 635,309 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, the general partner of Versant Ventures VI GP, the general partner of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP"), the general partner of Versant I Parallel. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 653,412 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,958,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F1 · ownership.nature: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). The Reporting Person may be deemed to beneficially own indirectly 6,413,332 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP"), the general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP"), the general partner of Versant VI. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), or for any other purpose. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 1,277,111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,277,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F4 · ownership.nature: Shares held by Versant Voyageurs I, L.P.("Versant Voyageurs I"). The Reporting Person may be deemed to beneficially own indirectly 2,130,579 shares of Common Stock by reason of the Reporting Person has a beneficial interest in Versant Voyageurs I GP Company, the general partner of Versant Voyageurs I. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 380,817 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 380,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F3 · ownership.nature: Shares held by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). The Reporting Person may be deemed to beneficially own indirectly 635,309 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, the general partner of Versant Ventures VI GP, the general partner of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP"), the general partner of Versant I Parallel. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 4,973,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,305,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F1 · ownership.nature: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). The Reporting Person may be deemed to beneficially own indirectly 6,413,332 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP"), the general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP"), the general partner of Versant VI. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), or for any other purpose. Read SEC document |
| November 19, 2019 Filed Nov 22, 2019 00:53 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 28,255 | $67.41 | $1,904,782.57 |
DisclosureSEC source: 0001209191-19-057685 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 596,741 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.35 to $73.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and pursuant to agreement with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| November 19, 2019 Filed Nov 22, 2019 00:53 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 13,745 | $67.41 | $926,605.43 |
DisclosureSEC source: 0001209191-19-057685 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.35 to $73.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 22:34 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 21,000 | $51.89 | $1,089,675.30 |
DisclosureSEC source: 0001209191-19-054773 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,745 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.73 to $52.11, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 21:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $43.52 | $0.00 |
DisclosureSEC source: 0000899243-19-016847 · doc4.xml · derivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2029-06-11 F2 · shares: The Reporting Person is a managing member of Versant Venture Management, LLC and pursuant to agreement with Versant Venture Management, LLC, the Reporting Person is deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F1 · derivative.exercise_date: This option was granted on June 11, 2019 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2019; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2020 Annual General Meeting of Shareholders. F2 · derivative.underlying_shares: The Reporting Person is a managing member of Versant Venture Management, LLC and pursuant to agreement with Versant Venture Management, LLC, the Reporting Person is deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · balance_after: The Reporting Person is a managing member of Versant Venture Management, LLC and pursuant to agreement with Versant Venture Management, LLC, the Reporting Person is deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · ownership.nature: The Reporting Person is a managing member of Versant Venture Management, LLC and pursuant to agreement with Versant Venture Management, LLC, the Reporting Person is deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 15, 2018 Filed Jun 16, 2018 01:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000899243-18-016878 · doc4.xml · derivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2028-06-15 F2 · shares: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Thomas Woiwode, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · shares: (Continued from Footnote #2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F1 · derivative.exercise_date: This option was granted on June 15, 2018 with 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018. F2 · derivative.underlying_shares: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Thomas Woiwode, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · derivative.underlying_shares: (Continued from Footnote #2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · balance_after: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Thomas Woiwode, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · balance_after: (Continued from Footnote #2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · ownership.nature: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Thomas Woiwode, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · ownership.nature: (Continued from Footnote #2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 15, 2018 Filed May 17, 2018 21:15 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,000 | $58.73 | $58,730.00 |
DisclosureSEC source: 0000899243-18-013244 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 640,014 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.585 to $58.785 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and may be deemed to indirectly beneficially own the shares through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 15, 2018 Filed May 17, 2018 21:15 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 43,000 | $57.97 | $2,492,710.00 |
DisclosureSEC source: 0000899243-18-013244 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 641,014 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.54 to $58.50 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and may be deemed to indirectly beneficially own the shares through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 08, 2018 Filed May 9, 2018 21:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,900 | $51.38 | $149,002.00 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 10 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,745 F11 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.51 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| May 08, 2018 Filed May 9, 2018 21:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 6,341 | $50.16 | $318,064.56 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 9 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,645 F11 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.66 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 582 | $51.26 | $29,833.32 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 8 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 90,730 F8 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. ("VVC CAN"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F9 · ownership.nature: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 249 | $51.26 | $12,763.74 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 38,772 F6 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F7 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 225 | $51.26 | $11,533.50 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 34,977 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F5 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 7,645 | $51.26 | $391,882.70 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,192,139 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 7,424 | $50.31 | $373,501.44 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 91,312 F8 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. ("VVC CAN"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F9 · ownership.nature: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,172 | $50.31 | $159,583.32 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 39,021 F6 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F7 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,862 | $50.31 | $143,987.22 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 35,202 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F5 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 97,550 | $50.31 | $4,907,740.50 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,199,784 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 30, 2018 Filed May 2, 2018 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,044 | $50.29 | $102,792.76 |
DisclosureSEC source: 0000899243-18-011132 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 98,736 F8 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. ("VVC CAN"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F9 · ownership.nature: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 30, 2018 Filed May 2, 2018 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 874 | $50.26 | $43,927.24 |
DisclosureSEC source: 0000899243-18-011132 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 42,193 F6 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F7 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 30, 2018 Filed May 2, 2018 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 788 | $50.29 | $39,628.52 |
DisclosureSEC source: 0000899243-18-011132 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 38,064 F4 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F5 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 30, 2018 Filed May 2, 2018 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 26,860 | $50.29 | $1,350,789.40 |
DisclosureSEC source: 0000899243-18-011132 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,297,334 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 27, 2018 Filed May 1, 2018 00:58 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 779 | $50.03 | $38,973.37 |
DisclosureSEC source: 0000899243-18-010985 · doc4.xml · nonDerivative · entry 8 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 100,780 F8 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. ("VVC CAN"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.21 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F9 · ownership.nature: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 27, 2018 Filed May 1, 2018 00:58 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 333 | $50.01 | $16,653.33 |
DisclosureSEC source: 0000899243-18-010985 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 43,067 F6 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.21 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F7 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 27, 2018 Filed May 1, 2018 00:58 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 300 | $50.08 | $15,024.00 |
DisclosureSEC source: 0000899243-18-010985 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 38,852 F4 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.21 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F5 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 27, 2018 Filed May 1, 2018 00:58 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 10,236 | $50.02 | $512,004.72 |
DisclosureSEC source: 0000899243-18-010985 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,324,194 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.21 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 26, 2018 Filed May 1, 2018 00:58 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 14,086 | $50.11 | $705,849.46 |
DisclosureSEC source: 0000899243-18-010985 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 101,559 F8 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. ("VVC CAN"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.45 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F9 · ownership.nature: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 26, 2018 Filed May 1, 2018 00:58 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 6,019 | $50.12 | $301,672.28 |
DisclosureSEC source: 0000899243-18-010985 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 43,400 F6 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.45 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F7 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 26, 2018 Filed May 1, 2018 00:58 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,430 | $50.12 | $272,151.60 |
DisclosureSEC source: 0000899243-18-010985 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 39,152 F4 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.45 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F5 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 26, 2018 Filed May 1, 2018 00:58 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 185,075 | $50.11 | $9,274,108.25 |
DisclosureSEC source: 0000899243-18-010985 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,334,430 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.45 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 20:57 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,528 | $51.00 | $77,928.00 |
DisclosureSEC source: 0000899243-18-010839 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 115,645 F8 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. ("VVC CAN"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F9 · ownership.nature: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 20:57 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 653 | $51.00 | $33,303.00 |
DisclosureSEC source: 0000899243-18-010839 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 49,419 F6 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F7 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.